IL-33/ST2在急性冠脉综合征中的研究进展

doi:10.12092/j.issn.1009-2501.2018.09.018

中国临床药理学与治疗学 ›› 2018, Vol. 23 ›› Issue (9): 1075-1080.doi: 10.12092/j.issn.1009-2501.2018.09.018

• 综述与讲座 • 上一篇

IL-33/ST2在急性冠脉综合征中的研究进展

张倩¹, 付红², 陈瑾瑾¹, 朱余兵¹

¹南京医科大学附属南京医院（南京市第一医院）药学部，南京 210006，江苏; ²重庆医科大学药学院，重庆 400016

收稿日期:2018-02-23 修回日期:2018-07-13 出版日期:2018-09-26 发布日期:2018-09-26
通讯作者: 朱余兵，男，副主任药师，主要研究方向：临床药学、药事管理。 Tel: 18951670305 E-mail: zyb86052002@163.com
作者简介:张倩，女，硕士，主管药师，主要研究方向：临床药学、药理学。 Tel: 13815413261 E-mail: zhangq0619@163.com
基金资助:
江苏省自然科学基金项目（BK20170140）；南京市药学会-常州四药医院药学科研基金项目（2017YX006）

Research progress of IL33/ST2 in acute coronary syndrome

ZHANG Qian¹, FU Hong², CHEN Jinjin¹, ZHU Yubing¹

¹Department of Pharmacy, Nanjing First Hospital, Nanjing 210006, Jiangsu, China; ² College of Pharmacy, Chongqing Medical University, Chongqing 400016, China

Received:2018-02-23 Revised:2018-07-13 Online:2018-09-26 Published:2018-09-26

摘要/Abstract

摘要：

白介素-33(interleukin33, IL-33)是IL-1免疫球蛋白家族的新成员，可与靶细胞膜上的生长刺激表达基因2蛋白（ST2）结合形成跨膜复合体，形成IL-33/ST2信号通路，参与了与Th2活化相关的许多炎症和免疫疾病。近年来许多研究发现IL-33/ST2信号通路在冠心病等心脑血管疾病中也起到重要的作用。急性冠脉综合征是冠心病的一种严重类型，本质是冠状动脉炎性病变后，斑块的破裂和侵蚀过程。本文综述IL-33/ST2信号在急性冠脉综合征中研究进展，希望为急性冠脉综合征的治疗提供新的靶点和思路。

关键词: 白细胞介素-33, 生长刺激表达基因2蛋白, 急性冠脉综合征

Abstract:

The interleukin-33 (IL-33), which is a new member of the Interleukin-1(IL-1) immunoglobulin family, binds to the target cell membrane growth-stimulating expression gene 2 (ST2) to form a trans membrane complex. The IL-33/ST2 signaling pathway is involved in many inflammatory and immune diseases with the activation of Th2. In recent years, many studies have reported that IL-33/ST2 signaling pathway also plays an important role in cardio- and cerebro-vascular diseases such as coronary heart disease. Acute coronary syndrome (ACS) is a serious type of coronary heart disease based on the process of plaque rupture and erosion following the inflammatory lesions of coronary artery. This article aims to provide a new target and idea for the treatment of acute coronary syndrome by reviewing the progress of the studies of IL-33/ST2 signaling in acute coronary syndrome.

Key words: interleukin-33, growth-stimulating expression gene 2, acute coronary syndrome

中图分类号:

R541.4

张倩, 付红, 陈瑾瑾, 朱余兵. IL-33/ST2在急性冠脉综合征中的研究进展[J]. 中国临床药理学与治疗学, 2018, 23(9): 1075-1080.

ZHANG Qian, FU Hong, CHEN Jinjin, ZHU Yubing. Research progress of IL33/ST2 in acute coronary syndrome[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2018, 23(9): 1075-1080.

参考文献

［1］刘善辉,张世超,吉尚戎.IL-33活性调节及在疾病中的调控作用［J］.生物学杂志,2017,34(3): 78-81.
［2］刘巍.非ST段抬高急性冠脉综合征的诊断及治疗2014年AHA/ACC NSTE-ACS指南解读［J］.中西医结合心血管病电子杂志,2015,(3):1-3.
［3］孙爱梅,陈还珍.IL-33/ST2信号通路在心血管疾病中的研究进展［J］.中华临床医师杂志,2016, 10(10):1484-1487.
［4］黄静,陈还珍,韩瑾,等.ST2在心血管疾病方面研究新进展［J］.中国医学创新,2016,13 (25): 87-89.
［5］肖伟,罗艺.小鼠局灶性脑缺血再灌注后IL-33及其受体的时程表达［J］.中风与神经疾病, 2017,34(3):202-207.
［6］McLaren JE,Michael DR,Salter RC,et al.IL-33 reduces macrophage foam cell formation.［J］.The Journal of Immunology,2010,185(2):1222-1229.
［7］徐成斌.急性冠脉综合征的病理与病理生理学［J］.中国医刊,2001,36(11):6-8.
［8］Lingel A,Weiss TM,Niebuhr M,et al. Structure of IL-33 and its interaction with the ST2 and IL-1RAcP receptors-insight into heterotrimeric IL-1 signaling complexes［J］. Structure,2009,7(10): 1398-1410.
［9］Kunes P,Mandak J,Holubcova,et al. Actual position of interleukin(IL)-33 in atherosclerosis and heart failure: Great Expectations or En attendant Godot［J］?Perfusion,2015,30(5):356-374.
［10］Dieplinger B,Mueller T.Soluble ST2 in heart failure［J］.Int J Clin Chem,2015,443:57-70.
［11］De la Fuente M, MacDonald TT, Hermoso MA. The IL-33/ST2 axis: Role in health and disease ［J］. Cytokine Growth Factor Rev, 2010,6(26):615-623.
［12］Guzel S,Serin O,Guzel EC,et al.Interleukin-33, matrix metalloproteinase-9, and tissue inhibitor ［corrected］ of matrix metalloproteinase-1 in myocardial infarction［J］.Korean J Intern Med,2013,2(28):165-173.
［13］Al Shahi H,Shimada K,Miyauchi K,et al. Elevated circulating levels of inflammatory markers in patients with acute coronary syndrome［J］.Int J Vasc Med,2015,2015:805375.
［14］Pfetsch V,Sanin V,Jaensch A.Increased plasma concentrations of soluble ST2 independently predict mortality but not cardiovascular events in stable coronary heart disease patients: 13-year follow-up of the KAROLA study［J］.Cardiovasc Drugs Ther,2017,31(2):167-177.
［15］施冰,吴龙梅,李俊峡,等.可溶性ST2检测在急性冠状动脉综合征的临床应用［J］.岭南心血管病杂志,2016,22(5):509-512.
［16］Eggers KM,Armstrong PW,Califf RM,et al.ST2 and mortality in non-ST-segment elevation acute coronary syndrome［J］.Am Heart J,2010,159(5):788-794.
［17］Kohli P,Bonaca MP,Kakkar R,et al. Role of ST2 in non-ST-elevation acute coronary syndrome in the MERLIN-TIMI 36 trial［J］.Clin Chem, 2012,58(1):257-266.
［18］Chen B,Geng J,Gao SX,et al Eplerenone modulates Interleukin-33/sST2 Signaling and IL-1β in left ventricular systolic dysfunction after acute myocardial infarction［J］.J Interferon Cytokine Res,2018,38(3):137-144.
［19］Sabatine MS,Morrow DA,Higgins LJ,et al.Complementary roles for biomarkers of biomechanical strain ST2 and N-terminal prohormone B-type natriuretic peptide in patients with ST-elevation myocardial infarction［J］.Circulation,2008,117(15):1936-1944.
［20］Yu J,Oh PC,Kim M,et al.Improved early risk stratification of patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention using a combination of serum soluble ST2 and NT-proBNP［J］.PloS one,2017,12(8):e0182829.
［21］Weir RA,Miller AM,Murphy G.Serum soluble ST2: a potential novel mediator in left ventricular and infarct remodeling after acute myocardial infarction［J］.J Am Coll Cardiol, 2010, 55 (3):243-250.
［22］Shimpo M,Morrow DA,Weinberg EO,et al.Serum levels of the interleukin-1 receptor family member ST2 predict mortality and clinical outcome in acute myocardial infarction ［J］.Circulation,2004,109(18):2186-2190.
［23］兰志明,刘鹏.ST2与冠心病的研究进展［J］.中国医药科学,2017,7(4):38-40.
［24］Lax A,Sanchez-Mas J,Asensio-Lopez MC,et al.Mineralocorticoid receptor antagonists modulate galectin-3 and Interleukin-33/ST2 signaling in left ventricular systolic dysfunction after acute myocardial Infarction［J］.JACC Heart Fail,2015,3(1):50-58.
［25］Veeraveedu PT,Sanada S,Okuda K,et al.Ablation of IL-33 gene exacerbate myocardial remodeling in mice with heart failure induced by mechanical stress［J］.Biochem Pharmacol, 2017, 138:73-80.
［26］Sánchez-Más J,Lax A,Asensio-López Mdel C,et al.Modulation of IL-33/ST2 system in post infarction heart failure: correlation with cardiac remodelling markers［J］.Eur J Clin Invest, 2014, 44 (7):643-651.
［27］Lupón J,Gaggin HK,de Antonio M,et al.Biomarker-assist score for reverse remodeling prediction in heart failure:The ST2-R2 score［J］.Int J Cardiol,2015,184:337-343.
［28］Moore SA,Januzzi JL Jr.Found in translation soluble ST2 and heart disease［J］.J Am Coll Cardiol, 2010,55(3):251-253.
［29］李惠,肖普马曹.ST2基因多态性与冠状动脉疾病的相关性［J］.中国老年学杂志, 2017, 37(8): 1917-1919.
［30］Tu X,Nie S,Liao Y,et al.The IL-33-ST2L pathway is associated with coronary artery disease in a Chinese Han population［J］.Am J Hum Genet,2013,93(4):652-660.
［31］Tsapaki A, Zaravinos A, Apostolakis S,et al.Genetic variability of the distal promoter of the ST2 gene is associated with coronary artery disease［J］.J Thromb Thrombolysis,2010,30 (3):365-371.
［32］Wu F,He M,Wen Q,et al.Associations between Variants in IL-33/ST2 Signaling Pathway Genes and Coronary Heart Disease Risk. Int J Mol Sci［J］.Int J Mol Sci,2014,15(12): 23227-23239.

[1]	庞胜峰, 张晶, 吴宁宁, 李茹, 曹军, 何胜虎. 急性冠脉综合征患者PCI术后短程双联抗栓后单用替格瑞洛的疗效观察[J]. 中国临床药理学与治疗学, 2022, 27(9): 1004-1009.
[2]	邓毅凡, 何胜虎, 王大新, 戴承晔, 徐笑挺, 张晶. 依折麦布联合他汀对急性冠脉综合征行急诊介入患者残粒脂蛋白胆固醇及MACE影响的临床研究[J]. 中国临床药理学与治疗学, 2021, 26(9): 1048-1052.
[3]	张宁汝，张恒，李妙男，孙强，王洪巨，汤阳. 高血压合并急性冠脉综合征患者P₄₅₀2C19基因多态性与氯吡格雷抵抗及冠状动脉介入术后近期预后关系探讨[J]. 中国临床药理学与治疗学, 2016, 21(4): 425-431.
[4]	章霞, 柯永胜. 新型P2Y12受体抑制剂替格瑞洛临床研究进展[J]. 中国临床药理学与治疗学, 2014, 19(4): 459-464.
[5]	周碧蓉, 陈越峰, 周娜, 杨景. 急性冠脉综合征患者血清高敏C反应蛋白和组织蛋白酶S水平变化与临床意义[J]. 中国临床药理学与治疗学, 2013, 18(9): 1036-1039.
[6]	张银妆, 陈碧莲. 抗血小板膜P₂Y₁₂受体拮抗剂的研究进展[J]. 中国临床药理学与治疗学, 2013, 18(7): 824-830.
[7]	贾亮亮, 柯永胜. 急性冠脉综合征患者接受经皮冠状动脉介入治疗前后抗凝策略[J]. 中国临床药理学与治疗学, 2013, 18(4): 469-475.
[8]	贾亮亮, 柯永胜. 急性冠脉综合征患者接受经皮冠状动脉介入治疗前后抗血小板策略[J]. 中国临床药理学与治疗学, 2012, 17(9): 1074-1080.
[9]	柯永胜. 新型抗凝药物直接Xa因子抑制剂利伐沙班[J]. 中国临床药理学与治疗学, 2009, 14(4): 361-367.
[10]	陈碧莲, 解勤之, 李清. 急性冠脉综合征患者氯吡格雷抵抗与近期疗效的临床观察[J]. 中国临床药理学与治疗学, 2009, 14(3): 328-332.
[11]	吴旭斌, 钱宗杰, 伍广伟, 林英忠, 胡昌兴. 罗格列酮对无糖尿病急性冠脉综合征患者外周血单核细胞合成TNF-α和组织因子的影响[J]. 中国临床药理学与治疗学, 2009, 14(2): 180-185.
[12]	吴旭斌, 汤圣兴, 伍广伟, 林英忠, 胡昌兴. 阿托伐他汀对急性冠脉综合征患者外周血单核细胞合成组织因子和TNF-α的影响[J]. 中国临床药理学与治疗学, 2009, 14(1): 98-102.
[13]	张品, 何胜虎, 陈述, 张惹, 严风姊, 燕建峰, 赵福全, 徐返华. 曲美他嗦对非ST段抬高急性冠脉综合征患者心肌缺血和心率变异的影响[J]. 中国临床药理学与治疗学, 2007, 12(12): 1432-1435.
[14]	刘彦, 陈绍良, 刘志忠. 急性冠脉综合症患者冠状动脉侧支的临床意义[J]. 中国临床药理学与治疗学, 2006, 11(6): 681-683.

IL-33/ST2在急性冠脉综合征中的研究进展

Research progress of IL33/ST2 in acute coronary syndrome

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 14

编辑推荐

Metrics

本文评价